JPMorgan Reinstates Stoke Therapeutics (STOK) at Neutral
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Price: $31.31 --0%
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 8
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 8
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Stoke Therapeutics (NASDAQ: STOK) with a Neutral rating and a price target of $6.00.
For an analyst ratings summary and ratings history on Stoke Therapeutics click here. For more ratings news on Stoke Therapeutics click here.
Shares of Stoke Therapeutics closed at $4.22 yesterday.
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- Goldman Sachs Starts Vail Resorts (MTN) at Sell
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
